Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Biote (BTMD) Long-Term Debt Repayments (2021)

Biote's quarterly Long-Term Debt Repayments came in at $164000.0 in Q1 2021.

Biote has reported Long-Term Debt Repayments for 1 years, with the latest figure at $164000.0 in Q1 2021.

  • For the quarter ending Q1 2021, Long-Term Debt Repayments changed N/A year-over-year to $164000.0; the trailing twelve-month figure through Dec 2021 stood at $164000.0 (changed N/A YoY), and the FY2021 full-year result was $164000.0, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q1 2021 stood at $164000.0.
  • The five-year high for Long-Term Debt Repayments was $164000.0 in Q1 2021, with the low at $164000.0 in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 HCA Healthcare 84.64 Bn 87.02 Bn 16.26 Bn 58.00 Mn
2 Tenet Healthcare 15.22 Bn 14.39 Bn 4.41 Bn 33.00 Mn
3 Davita 13.10 Bn 13.96 Bn 1.07 Bn 917.09 Mn
4 Encompass Health 10.50 Bn 11.12 Bn 1.34 Bn 330.00 Mn
5 Ensign 9.69 Bn 9.09 Bn 293.37 Mn 1.04 Mn
6 Universal Health Services 8.92 Bn 8.88 Bn 3.21 Bn 44.73 Mn
7 Fresenius Medical Care AG 7.31 Bn 4.93 Bn 22,843.10 Bn -
8 Chemed 5.83 Bn 5.81 Bn 215.76 Mn 44.28 Mn
9 Pacs 5.76 Bn 5.51 Bn 345.96 Mn -
10 Biote 61.29 Mn 64.11 Mn 30.95 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2021 164,000.00
Mar 31, 2021 164,000.00